Prestige BioPharma’s Tuznue receives EU-GMP certification

Resolution Therapeutics strengthens its team with two new appointments

Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance

Poxel’s PXL065 granted FDA fast track designation for X-linked adrenoleukodystrophy

Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear

Kato wins USFDA approval for studies in retinal disorder

Resolv ER may remedy leading causes of blindness in adults

Maharasthra Health Minister inaugurates BSV research centre at Airoli, Maharashtra

The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems

Noorik Biopharma signs contract with Switzerland to develop ambrisentan to treat severe Covid-19

The primary objective of the ongoing trial is to determine whether ambrisentan can prevent the progression to respiratory failure and reduce the need for mechanical ventilation, among others

Glenmark subsidiary, Ichnos Sciences and Almirall enter exclusive licencing agreement

Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales

Medicago and GSK’s plant based Covid-19 vaccine candidate show promise in Phase 3 trials

Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants

Nykode Therapeutics enters multi-target license and collaboration agreement with Regeneron

The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease

Aadi Bioscience secures U.S FDA approval of its first product Fyarro

Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults